CHMP adopts positive opinion on Yuviwel for achondroplasia
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 15 October 2026, recommending marketing authorisation for Yuviwel (navepegritide) for children 2 years and older with achondroplasia. The opinion notes that Yuviwel improves annualised growth velocity by 1.49 cm versus placebo in a 52-week trial.
Primary source
EMA medicine page (CHMP opinion), October 16, 2026
Yuviwel (Navepegritide): EMA CHMP opinion
Read the source: Yuviwel (Navepegritide): EMA CHMP opinion ema.europa.eu
Machine-summarized from the source above; not independently reported. How we use automation